Antibiotic resistance has been a growing threat to human health for several years. Effectiveness of many antibacterial agents has declined worldwide, thus, limiting physicians' options to treat serious infections. The World Health Organization has stated that antibiotic resistance is one of the greatest healthcare challenges for the future. V-PHARMA would like to devote resources to work on a class of compounds to address this problem collaboratively.
Partnership: V-PHARMA is open to collaboration to realize its business goals. This is a risk-sharing approach where both the client and V-PHARMA put their own resources together to achieve the project goals. If successful, both parties share in the return on investment. IP is negotiated between the parties as part of the agreement. V-PHARMA is continuously looking for opportunities/collaborators to start any small molecule drug discovery effort, including metabolic disorders.
This is one of the most viable arrangements in which approved resources are allocated to a project for a fixed period of time. All intellectual property rights or know-how derived from the project belong to the client upon signing the agreement.
The company's electronic notebook allows clients to keep track of the work that is taking place. In addition to the electronic notebook, meetings with the client are scheduled at least bi-weekly to review progress. V-PHARMA tries to understand the target product profile (TPP), reviews the literature, and can contribute both technically and intellectually to the success of the drug discovery projects.
Full-time equivalents are committed to full-time to the sponsor. These contracts provide our clients with reliable laboratory capacity. On the other hand, in a one-off situation, timely project start-ups may be delayed.
The dynamics of the drug discovery environment are such that goals change. As an example, chemical or biological data may favor a new lead. Thus, the scale-up synthesis of a target molecule may need to be changed or suspended. This approach allows for projects to be altered quickly without the need to adjust a work order.
There is no time lapse for proposal writing and contract approval processes when there is a need to change the priorities or to initiate new chemistry.
Medicinal Chemistry focuses on modifications of leads generated from natural compounds, high-throughput screening, and knowledge of validated therapeutic targets. Modern synthetic organic chemistry, including advanced purification and spectroscopic technology is applied to finish the structure-activity relationship studies.
We Can Contribute to Your Medicinal Chemistry Projects in the Different Stages of Drug Discovery:
Designated sets of small molecules or analogs can be synthesized for hit-to-lead identification programs. V-PHARMA can also help identify the lead by analyzing the competitors’ and pharmacological landscape (for validated targets) and initiating the fast follower program if needed. We can also contribute to the opportunistic chemistry approach programs.
Following a client-driven approach, we can prepare tailor-designed molecules to improve the most promising compounds' potency and drug-like properties. We can integrate all currently available medicinal chemistry principles to make high-quality molecules- a top priority, thereby shortening the time required to select the right pre-clinical candidate.
We can synthesize non-commercially available screening compounds; thus increasing the commercial diversity and exclusivity of your chemical library. We can make every effort to identify the privileged scaffolds/drug-like chemotypes with known/unknown pharmacophores.
We can help gain wider and stronger IP protection when submitting a patent application by expanding the chemical diversity of the exemplified compounds. V-PHARMA can work with patent attorneys while filing the patent applications.
Evaluations of the client's proposal and design of new routes of synthesis (ROS) can take part as well. This exercise is always done with a scale-up and industrialization mindset. We optimize the synthetic scheme of the desired pre-candidate or clinical candidate molecule. This will allow us to make several hundred grams to kilo quantitie
Evaluations of the client's proposal and design of new routes of synthesis (ROS) can take part as well. This exercise is always done with a scale-up and industrialization mindset. We optimize the synthetic scheme of the desired pre-candidate or clinical candidate molecule. This will allow us to make several hundred grams to kilo quantities in a non-GMP manner and may also serve as a starting point to further optimize and/or make bulk quantities of the potential drug substance during a later stage of the drug development.
Single Compound (One-offs) projects are tender at an assured fixed price for labor. The raw materials are either included in the fixed price or back-charged at cost. One-off projects typically involve large quantities of material (generally 50g to Kilograms).
Respectable relationships are essential to the success of all outsourcing enterprises. We typically undertake one-off projects initially where V-PHARMA assumes the risk during the crucial getting acquainted period. If mutually agreed to, shared risk can then be considered. This may involve to FTEs.
We can also strive to maximize value for clients through our operations. For example, FTE projects support a full-service kilo lab through V-PHARMA’s strategic partners to make unavailable raw materials. This allows considerable budget flexibility and value to ensure that projects will not be delayed.
The library design and synthesis service are dedicated to examining, producing, and designing a wide range of small organic molecule libraries for pharmaceutical companies, research groups, and biotechnology companies. The library is created both by the customers’ demands and our company’s knowledge, capabilities, and molecular modeling skills. The compounds can also be purified based on the customer’s requirements, and V-PHARMA can randomly synthesize part of a library in advance. We work with our clients and other computational chemists to supply specific targeted groups.
The advances in understanding the molecular basis of diseases have facilitated increasing the design and development of new drug candidates. This also helped in identifying a number of novel therapeutic targets. Improving chemotype diversity is critical to the biological activity and potential of the compound to be developed as a drug. The presence of strategically placed carbon-hetero bonds is the key to the function of biologically active molecules. E.g., Nitrogen modification can significantly affect drug action, thus making it the heteroatom of choice for structure-activity relationships (SAR) studies of biologically active molecules.
The catalog of advanced heterocycles and important organic compounds initiative was introduced in 2011. The objective is to provide new building blocks that are not readily available, including those known in the literature. These building blocks are expected to address some of the problems incurred in drug discovery. The problems include protein-binding, stability, enhance solubility in physiological media, and/or modified P450 metabolic processes. V-PHARMA hopes to fill this niche using a concise progression of core structures, containing at least two functional groups.
The design of novel building blocks, templates, chemotypes, scaffolds, privileged structures or small fragments for Small Fragment-Based Drug Discovery is critical to developing diversity and originality in the modern drug discovery enterprise. These structures are linchpin points that chemists can use as a basis for the construction of more complex molecular structures with the right pharmacophores. With in-house expertise and new methodologies, V-PHARMA has built a catalog of several thousand structures for drug discovery or screening purposes. The V-PHARMA's design of catalog of compounds is directed primarily by scientific (pharmaceutical and chemistry) and business considerations. These molecules can be ordered directly from stock (or order as a request) from several milligrams to a couple of hundred grams to support pharmaceutical and related research.
The compounds are routinely supplied in research quantities from stock or made with a short lead time. The strategic partner’s facility allows us to offer many of these intermediates in 1kg to multi-kilogram quantities with lead times to be defined, depending on complexity. This allows V-PHARMA to maintain links with clients throughout the development of new chemical entity/drug candidates and to avoid supply interruptions during the project progression. In addition to its in-house chemical developments, and to help support customers' needs, V-PHARMA has undertaken strategic collaborations to strengthen and support the growth of the catalog.